First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis

Authors :: Kasenda, B.
Ferreri, A. J. M.
Marturano, E.
Forst, D.
Bromberg, J.
Ghesquieres, H.
Ferlay, C.
Blay, J. Y.
Hoang-Xuan, K.
Pulczynski, E. J.
Fosså, A.
Okoshi, Y.
Chiba, S.
Fritsch, K.
Omuro, A.
O'Neill, B. P.
Bairey, O.
Schandelmaier, S.
Gloy, V.
Bhatnagar, N.
Haug, S.
Rahner, S.
Batchelor, T. T.
Illerhaus, G.
Briel, M.
Kasenda, B.
Ferreri, A. J. M.
Marturano, E.
Forst, D.
Bromberg, J.
Ghesquieres, H.
Ferlay, C.
Blay, J. Y.
Hoang-Xuan, K.
Pulczynski, E. J.
Fosså, A.
Okoshi, Y.
Chiba, S.
Fritsch, K.
Omuro, A.
O'Neill, B. P.
Bairey, O.
Schandelmaier, S.
Gloy, V.
Bhatnagar, N.
Haug, S.
Rahner, S.
Batchelor, T. T.
Illerhaus, G.
Briel, M.
Abstract: Evidence for prognosis and treatment of elderly patient with primary central nervous system is limited. High-dose methotrexate should be applied whenever possible, especially combination with oral alkylating agents is a promising approach. Further combinations with other intravenous drugs do not seem to improve outcome. More prospective trials designed for elderly PCNSL patients are warranted

Tools